Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis

Among 118,341 T2DM patients using metformin, cardiovascular risk was lower in users of sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, and glucagon-like peptide 1 agonists compared to sulfonylurea users.

• During a median follow-up of 10 months, users of SGLT-2 inhibitors had a 39% lower risk of cardiovascular events compared to sulfonylurea users.
• Dipeptidyl peptidase-4 inhibitor users experienced a 21% reduction in cardiovascular risk compared to those using sulfonylureas.
• Glucagon-like peptide 1 agonist users showed a 35% lower risk of cardiovascular events relative to sulfonylurea users.
• Serious adverse events were rare across all groups but were lower in users of novel glucose lowering agents compared to sulfonylureas.
• The cohort primarily consisted of patients at low cardiovascular risk, with only 4% having a history of cardiovascular or cerebrovascular events.

AI simplified